Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Prognostic factors on overall survival and progression-free survival by Cox proportional-hazards model

From: Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis

  Overall survival Progression-free survival
  Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Variables HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (<50 vs. ≥50) 1.21 (0.59-2.51) 0.61    1.24 (0.69-2.21) 0.47   
ECOG PS (0 vs. 1 or 2) 0.45 (0.22-0.95) 0.04 0.53 (0.25-1.12) 0.1 0.48 (0.27-0.87) 0.02 0.57 (0.31-1.03) 0.06
Tumor shape (exophytic vs. infiltrative) 1.75 (0.85-3.64) 0.13    1.75 (0.98-3.14) 0.06 1.67 (0.93-2.99) 0.09
Tumor size (<5 vs. ≥5 cm) 0.67 (0.3-1.47) 0.31    0.72 (0.39-1.33) 0.29   
Parametrial involvement (no vs. yes) 0.4 (0.1-1.7) 0.22    0.5 (0.18-1.39) 0.18   
Endocervical extension (others vs. yes) 1.85 (0.82-4.17) 0.14    1.47 (0.8-2.7) 0.22   
Pelvic nodal involvement (no vs. yes) 0.78 (0.32-1.91) 0.58    0.71 (0.34-1.47) 0.35   
Hydronephrosis (no vs. yes) 1.21 (0.42-3.5) 0.72    0.82 (0.4-1.65) 0.57   
Stage (IB vs. IIB vs. IIIA-IVA) Referent 0.38 (0.09-1.7) 0.45    Referent 0.45 (0.15-1.3) 0.32   
0.9 (0.42-1.92)     0.81 (0.44-1.49)    
Radiotherapy duration (<10 vs. ≥10 weeks) 0.59 (0.28-1.23) 0.16    0.62 (0.35-1.12) 0.11   
Doses to point A (<75 vs. ≥75 Gy) 0.87 (0.42-1.8) 0.71    0.64 (0.36-1.15) 0.14   
Doses to PAN (<50.4 vs. ≥50.4 Gy) 1.09 (0.46-2.55) 0.85    0.75 (0.35-1.6) 0.45   
Treatment period (<2000 vs. ≥2000) 1.25 (0.59-2.65) 0.56    0.98 (0.54-1.76) 0.95   
Treatment response (CR vs. PR) 0.36 (0.16-0.81) 0.01 0.43 (0.19-0.98) 0.04 0.27 (0.14-0.51) <0.001 0.3 (0.16-0.58) <0.001
Concurrent chemotherapy (no vs. yes) 1.23 (0.59-2.54) 0.59    0.88 (0.49-1.57) 0.65   
  1. Abbreviation: ECOG PS Eastern Cooperative Oncology Group performance status, CR complete remission, PR partial response, HR hazard ratio, CI confidence interval.
Back to article page